EMEA-002752-PIP01-19
Key facts
| Active substance |
IMG-2789
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0220/2020
|
| PIP number |
EMEA-002752-PIP01-19
|
| Pharmaceutical form(s) |
Capsule, hard
|
| Condition(s) / indication(s) |
Treatment of myeloproliferative neoplasms
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Merck Sharp & Dohme (Europe) Inc.
Tel. +33 180464738 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|